Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 276850, 12 pages
Review Article

Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases

1Department of Gastroenterology, Xiangya Hospital Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China
2GI Liver Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
3Department of Nutritional Science and Food Management, College of Health Science, Ewha Womans University, Seoul 150-750, Republic of Korea
4Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Davis Building 2094A, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA

Received 9 October 2014; Accepted 26 November 2014

Academic Editor: Caigan Du

Copyright © 2015 Ting Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Most chronic liver diseases (CLDs) are characterized by inflammatory processes with aberrant expressions of various pro- and anti-inflammatory mediators in the liver. These mediators are the driving force of many inflammatory liver disorders, which often result in fibrosis, cirrhosis, and liver tumorigenesis. c-Myc is involved in many cellular events such as cell growth, proliferation, and differentiation. c-Myc upregulates IL-8, IL-10, TNF-α, and TGF-β, while IL-1, IL-2, IL-4, TNF-α, and TGF-β promote c-Myc expression. Their interactions play a central role in fibrosis, cirrhosis, and liver cancer. Molecular interference of their interactions offers possible therapeutic potential for CLDs. In this review, current knowledge of the molecular interactions between c-Myc and various well known inflammatory mediators is discussed.